Literature DB >> 30464786

Long-Term Outcomes of a Cardiovascular and Diabetes Risk-Reduction Program Initiated by a Self-Insured Employer.

Nicole D White1, Thomas L Lenz2, Maryann Z Skrabal1, Jessica J Skradski3, Louis Lipari4.   

Abstract

BACKGROUND: Cardiovascular disease remains the leading cause of death in America and poses a significant challenge for self-insured employers attempting to improve employee health and well-being while controlling healthcare costs. Disease state management programs can be an effective means of achieving these outcomes, but the durability and long-term effects of such programs have limited evaluation.
OBJECTIVE: To assess the 5-year health, economic, and quality-of-life patient outcomes of an employer-sponsored disease state management program.
METHODS: This was a longitudinal, 5-year, quasi-experimental, pre-/postenrollment study. Self-insured health plan members with hypertension, hyperlipidemia, diabetes, or a combination of these conditions met with a pharmacist regularly (monthly for the first year, then varied by participant) to implement lifestyle medicine programs, optimize medication therapy, and facilitate the coordination of care. Biometric markers, lifestyle behaviors, quality of life, and work productivity were assessed on an annual basis.
RESULTS: The significant biometric improvements (mean) seen after 5 years of program participation compared with pre-enrollment included decreased low-density lipoprotein cholesterol levels (96.71 mg/dL vs 84.83 mg/dL, respectively), increased high-density lipoprotein cholesterol levels (39.32 mg/dL vs 46.12 mg/dL), and decreased systolic blood pressure (132.04 mm Hg vs 123.63 mm Hg) and diastolic blood pressure (85.75 mm Hg vs 75.83 mm Hg). The average exercise time increased (50 minutes weekly vs 156.04 minutes weekly), as did fruit and vegetable consumption (3.98 servings daily vs 5.27 servings daily). The program participants reported improved general health and a reduced number of unhealthy days. The combined healthcare and productivity return on investment for the program at 5 years was $9.64 for every $1 invested.
CONCLUSIONS: Significant changes in employees' health, well-being, and health-related costs are possible through sustained participation in an employer-sponsored disease state management program.

Entities:  

Keywords:  cardiovascular disease; cardiovascular risk; diabetes; disease management; employer-sponsored program; healthcare cost; lifestyle behavior; quality of life; risk reduction; work productivity

Year:  2018        PMID: 30464786      PMCID: PMC6207306     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


  18 in total

1.  The validity and reproducibility of a work productivity and activity impairment instrument.

Authors:  M C Reilly; A S Zbrozek; E M Dukes
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

Review 2.  3. Comprehensive Medical Evaluation and Assessment of Comorbidities.

Authors: 
Journal:  Diabetes Care       Date:  2017-01       Impact factor: 19.112

3.  Development and implementation of the compensation plan for pharmacy services in Alberta, Canada.

Authors:  Rene R Breault; Jeff G Whissell; Christine A Hughes; Theresa J Schindel
Journal:  J Am Pharm Assoc (2003)       Date:  2017-06-15

4.  The hickory project: controlling healthcare costs and improving outcomes for diabetes using the asheville project model.

Authors:  Barry A Bunting; Grover Lee; Grant Knowles; Christine Lee; Paul Allen
Journal:  Am Health Drug Benefits       Date:  2011-09

5.  National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.

Authors:  Terry A Jacobson; Matthew K Ito; Kevin C Maki; Carl E Orringer; Harold E Bays; Peter H Jones; James M McKenney; Scott M Grundy; Edward A Gill; Robert A Wild; Don P Wilson; W Virgil Brown
Journal:  J Clin Lipidol       Date:  2014-07-15       Impact factor: 4.766

6.  Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial.

Authors:  S H Simpson; D A Lier; S R Majumdar; R T Tsuyuki; R Z Lewanczuk; R Spooner; J A Johnson
Journal:  Diabet Med       Date:  2015-02-02       Impact factor: 4.359

7.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

8.  Comparison of cardiovascular risk calculation tools in pharmacy practice.

Authors:  Nicole D White; Thomas L Lenz; Maryann Z Skrabal; Michele A Faulkner; Jessica J Skradski; Leslie A Southard; Derek E Popken
Journal:  J Am Pharm Assoc (2003)       Date:  2013 Jul-Aug

Review 9.  Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.

Authors:  Caroline S Fox; Sherita Hill Golden; Cheryl Anderson; George A Bray; Lora E Burke; Ian H de Boer; Prakash Deedwania; Robert H Eckel; Abby G Ershow; Judith Fradkin; Silvio E Inzucchi; Mikhail Kosiborod; Robert G Nelson; Mahesh J Patel; Michael Pignone; Laurie Quinn; Philip R Schauer; Elizabeth Selvin; Dorothea K Vafiadis
Journal:  Circulation       Date:  2015-08-05       Impact factor: 29.690

10.  The study of health coaching: the ithaca coaching project, research design, and future directions.

Authors:  Gary A Sforzo
Journal:  Glob Adv Health Med       Date:  2013-05
View more
  1 in total

Review 1.  Academic Training, Knowledge, and Perceptions of Physical Activity in Student Pharmacists.

Authors:  Nicole White
Journal:  Am J Lifestyle Med       Date:  2021-01-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.